{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:03Z","timestamp":1792783383498,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rutgers University","id":[{"id":"https:\/\/ror.org\/05vt9qd57","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To assess the diagnostic accuracy of novel imaging modalities in working up invasive bladder cancer prior to surgical management and their potential role in guiding treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Multiple new imaging modalities, including VI-RADS and Biparametric MRI have been developed to better guide management of invasive bladder cancer. There lacks a comprehensive review of these modalities and their diagnostic performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We performed a systematic review following PRISMA guidelines. PubMed, Embase, and Scopus were searched through 2025. Studies reporting sensitivity and specificity of novel imaging for muscle invasion detection or nodal staging were included. Quality assessment used the QUADAS 2 tool. Thirty three studies encompassing 4,689 patients were included. Twenty three studies evaluated the Vesical Imaging Reporting and Data System for muscle invasion detection, achieving median sensitivity of 94% and specificity of 82% at a threshold of three or greater and 84% and 92%, respectively, at four or greater. Nine studies assessed positron emission tomography for nodal staging, with fluorodeoxyglucose positron emission tomography\/computed tomography demonstrating superior sensitivity (23 to 81%) compared to conventional computed tomography (13 to 47%). Fibroblast activation protein inhibitor tracers showed the highest sensitivity (82 to 100%) with specificity of 82 to 90%. One radiomics study achieved 73% sensitivity and 84% specificity for lymph node detection. Novel imaging modalities demonstrate promising diagnostic accuracy for bladder cancer staging. The Vesical Imaging Reporting and Data System provides reliable muscle invasion assessment with threshold dependent performance. Positron emission tomography with fibroblast activation protein inhibitor tracers substantially improves nodal staging over conventional computed tomography. Integration of these modalities may optimize patient management, including use or omission of neoadjuvant therapy and consideration for organ sparing approaches. Prospective multicenter validation is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11934-026-01370-z","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:42:13Z","timestamp":1792665733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Imaging Techniques Prior to Surgical Management of Invasive Bladder Cancer: A Systematic Review"],"prefix":"10.1007","volume":"27","author":[{"given":"Mahmoud","family":"Hijazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Golombos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"1","key":"1370_CR1","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043.","journal-title":"CA Cancer J Clin"},{"key":"1370_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003981","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024). J Urol. 2024. https:\/\/doi.org\/10.1097\/JU.0000000000003981.","journal-title":"J Urol"},{"issue":"1","key":"1370_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","volume":"55","author":"A Shabsigh","year":"2009","unstructured":"Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55(1):164\u201374.","journal-title":"Eur Urol"},{"issue":"4","key":"1370_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00345-018-2439-8","volume":"37","author":"J Crozier","year":"2019","unstructured":"Crozier J, Papa N, Perera M, et al. Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J Urol. 2019;37(4):667\u201390.","journal-title":"World J Urol"},{"issue":"6","key":"1370_CR5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving trimodality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol. 2017;71(6):952\u201360.","journal-title":"Eur Urol"},{"issue":"6","key":"1370_CR6","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.21037\/tau.2020.03.04","volume":"9","author":"TC Peak","year":"2020","unstructured":"Peak TC, Hemal A. Partial cystectomy for muscle-invasive bladder cancer: a review of the literature. Transl Androl Urol. 2020;9(6):2938\u201345.","journal-title":"Transl Androl Urol"},{"issue":"2","key":"1370_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ucl.2015.02.002","volume":"42","author":"C Premo","year":"2015","unstructured":"Premo C, Apolo AB, Agarwal PK, Citrin DE. Trimodality therapy in bladder cancer: who, what, and when? Urol Clin North Am. 2015;42(2):169\u201380.","journal-title":"Urol Clin North Am"},{"key":"1370_CR8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"3","key":"1370_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol. 2018;74(3):294\u2013306.","journal-title":"Eur Urol"},{"issue":"3","key":"1370_CR10","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1007\/s00330-020-07224-7","volume":"31","author":"H Ahn","year":"2021","unstructured":"Ahn H, Hwang SI, Lee HJ, et al. Quantitation of bladder cancer for the prediction of muscle layer invasion as a complement to the Vesical Imaging-Reporting and Data System. Eur Radiol. 2021;31(3):1656\u201366.","journal-title":"Eur Radiol"},{"issue":"1","key":"1370_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.euf.2023.08.004","volume":"10","author":"Y Arita","year":"2024","unstructured":"Arita Y, Kwee TC, Woo S, et al. Biparametric versus multiparametric magnetic resonance imaging for assessing muscle invasion in bladder urothelial carcinoma with variant histology using the Vesical Imaging-Reporting and Data System. Eur Urol Focus. 2024;10(1):131\u201338.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1370_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.euo.2022.07.006","volume":"6","author":"Y Arita","year":"2023","unstructured":"Arita Y, Yoshida S, Shigeta K, et al. Diagnostic value of the Vesical Imaging-Reporting and Data System in bladder urothelial carcinoma with variant histology. Eur Urol Oncol. 2023;6(1):99\u2013102.","journal-title":"Eur Urol Oncol"},{"key":"1370_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-025-04852-9","author":"S Aslan","year":"2025","unstructured":"Aslan S, Tasdemir MN, Cakir E, Oguz U, Tok B. Predicting variant histology in bladder cancer: the role of multiparametric MRI and vesical imaging-reporting and data system (VI-RADS). Abdom Radiol (NY). 2025. https:\/\/doi.org\/10.1007\/s00261-025-04852-9.","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"1370_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40644-022-00459-1","volume":"22","author":"TGM Bricio","year":"2022","unstructured":"Bricio TGM, Gouvea GL, Barros RV, et al. What is the impact of dynamic contrast-enhancement sequence in the Vesical Imaging, Reporting and Data System (VI-RADS)? A subgroup analysis. Cancer Imaging. 2022;22(1):20.","journal-title":"Cancer Imaging"},{"issue":"5","key":"1370_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/bju.15188","volume":"126","author":"F Del Giudice","year":"2020","unstructured":"Del Giudice F, Leonardo C, Simone G, et al. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothlial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy. BJU Int. 2020;126(5):610\u201319.","journal-title":"BJU Int"},{"key":"1370_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2025.112104","volume":"187","author":"MB Do\u011fan","year":"2025","unstructured":"Do\u011fan MB, G\u00fcnd\u00fcz N, Kazan H\u00d6, \u00c7ak\u0131c\u0131 M\u00c7, Y\u0131ld\u0131r\u0131m A, Erdem G. Contribution of lesion shape features to the VI-RADS for predicting muscle invasion in bladder tumors. Eur J Radiol. 2025;187:112104.","journal-title":"Eur J Radiol"},{"key":"1370_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s43055-023-01181-z","author":"N Elshewy","year":"2024","unstructured":"Elshewy N, Ramadan AA, Sameh WM, Eid MEED, El Achy S, Ezz Eldin O. A proposed inclusion of magnetic resonance imaging features to the VI-RADS to enhance its accuracy in predicting muscle invasion. Egypt J Radiol Nucl Med. 2024. https:\/\/doi.org\/10.1186\/s43055-023-01181-z.","journal-title":"Egypt J Radiol Nucl Med"},{"issue":"3","key":"1370_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/jmri.29184","volume":"60","author":"Y Gong","year":"2024","unstructured":"Gong Y, Cheng Y, Zhang J, et al. Role of additional MRI-based morphologic measurements on the performance of VI-RADS for muscle-invasive bladder cancer. J Magn Reson Imaging. 2024;60(3):1113\u201323.","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"1370_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajur.2024.06.001","volume":"12","author":"H Gungor","year":"2025","unstructured":"Gungor H, Camtosun A, Topcu I, Karaca L. Evaluating the concordance between Vesical Imaging Reporting and Data System scores and bladder tumor histopathology. Asian J Urol. 2025;12(1):87\u201392.","journal-title":"Asian J Urol"},{"issue":"3","key":"1370_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/03915603231151738","volume":"90","author":"P Gupta","year":"2023","unstructured":"Gupta P, Sarangi SS, Singh M, et al. To determine correlation between VIRADS scoring and pathological staging in bladder cancer: a prospective study and review of literature. Urologia. 2023;90(3):476\u201381.","journal-title":"Urologia"},{"issue":"1","key":"1370_CR21","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/j.urolonc.2022.09.026","volume":"41","author":"EH Huele","year":"2023","unstructured":"Huele EH, Veenboer PW, Wessels FJ, Jonges TN, Meijer RP. Value of multiparametric magnetic resonance imaging for local staging of invasive urinary bladder tumours. Urol Oncol. 2023;41(1):e497\u20134912.","journal-title":"Urol Oncol"},{"key":"1370_CR22","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.5114\/pjr.2023.130807","volume":"88","author":"NU Islam","year":"2023","unstructured":"Islam NU, Jehangir M, Parry AH, Nazir SS, Bilal S. Diagnostic performance of multiparametric MRI based Vesical Imaging-Reporting and Data System (VI-RADS) scoring in discriminating between non-muscle invasive and muscle invasive bladder cancer. Pol J Radiol. 2023;88:e356\u201364.","journal-title":"Pol J Radiol"},{"issue":"6","key":"1370_CR23","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4111\/icu.20230120","volume":"64","author":"C Jai-Ua","year":"2023","unstructured":"Jai-Ua C, Limpaiboon C, Siriboonrid S, et al. Accuracy of Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer detection from multiparametric magnetic resonance imaging. Investig Clin Urol. 2023;64(6):546\u201353.","journal-title":"Investig Clin Urol"},{"issue":"10","key":"1370_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.acuro.2023.04.001","volume":"47","author":"O Kazan","year":"2023","unstructured":"Kazan O, Gunduz N, Bakir B, et al. Diagnostic validity of the Vesical Imaging-Reporting and Data System (VI-RADS): a real-world study. Actas Urol Esp (Engl Ed). 2023;47(10):638\u201344.","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"2","key":"1370_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.21037\/tau-22-704","volume":"12","author":"SH Kim","year":"2023","unstructured":"Kim SH, Han JH, Jeong SH, et al. Accuracy of actual stage prediction using Vesical Imaging Reporting and Data System (VI-RADS) before radical cystectomy for urothelial carcinoma in SUPER-UC-Cx. Transl Androl Urol. 2023;12(2):168\u201375.","journal-title":"Transl Androl Urol"},{"issue":"2","key":"1370_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.acra.2023.09.005","volume":"31","author":"L Kong","year":"2024","unstructured":"Kong L, Wen Z, Cai Q, et al. Amide proton transfer-weighted MRI and diffusion-weighted imaging in bladder cancer: a complementary tool to the VI-RADS. Acad Radiol. 2024;31(2):564\u201371.","journal-title":"Acad Radiol"},{"issue":"2","key":"1370_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.21037\/tau.2020.02.16","volume":"9","author":"S Liu","year":"2020","unstructured":"Liu S, Xu F, Xu T, Yan Y, Yao X, Tang G. Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. Transl Androl Urol. 2020;9(2):445\u201351.","journal-title":"Transl Androl Urol"},{"issue":"9","key":"1370_CR28","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1007\/s00330-021-07765-5","volume":"31","author":"MI Metwally","year":"2021","unstructured":"Metwally MI, Zeed NA, Hamed EM, et al. The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. Eur Radiol. 2021;31(9):6949\u201361.","journal-title":"Eur Radiol"},{"key":"1370_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.urology.2024.10.002","volume":"194","author":"MS \u00d6zdemir","year":"2024","unstructured":"\u00d6zdemir MS, Keskin E, Savun M, Y\u00fczkan S, Kaya N, \u00d6zdemir H. VI-RADS-based algorithm for bladder cancer management randomized retrospective study. Urology. 2024;194:225\u201330.","journal-title":"Urology"},{"issue":"22","key":"1370_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13226955","volume":"13","author":"F Piramide","year":"2024","unstructured":"Piramide F, Sica M, Fondello G, et al. Use of multiparametric and biparametric magnetic resonance imaging in bladder cancer staging: prospective observational study and analysis of radiologist learning curve. J Clin Med. 2024;13(22):6955.","journal-title":"J Clin Med"},{"issue":"5","key":"1370_CR31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2214\/AJR.20.23604","volume":"216","author":"Y Ueno","year":"2021","unstructured":"Ueno Y, Tamada T, Takeuchi M, et al. VI-RADS: multiinstitutional multireader diagnostic accuracy and interobserver agreement study. AJR Am J Roentgenol. 2021;216(5):1257\u201366.","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"1370_CR32","doi-asserted-by":"publisher","first-page":"e100002","DOI":"10.1136\/bmjopen-2025-100002","volume":"15","author":"SW van Koeverden","year":"2025","unstructured":"van Koeverden SW, van Hoogstraten LM, de Rooij M, et al. Multiparametric MRI for local staging in patients with suspected muscle-invasive bladder cancer: study protocol for a multicentre, non-inferiority randomised controlled trial (the BladParadigm study). BMJ Open. 2025;15(8):e100002.","journal-title":"BMJ Open"},{"issue":"4","key":"1370_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/bco2.304","volume":"5","author":"M Al-Zubaidi","year":"2024","unstructured":"Al-Zubaidi M, Ong K, Viswambaram P, et al. Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial\/bladder cancer. BJUI Compass. 2024;5(4):473\u201379.","journal-title":"BJUI Compass"},{"issue":"3","key":"1370_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clgc.2022.01.009","volume":"20","author":"P Bertolaso","year":"2022","unstructured":"Bertolaso P, Brouste V, Cazeau AL, et al. Impact of 18F-FDG PET\/CT in the management of muscle invasive bladder cancer. Clin Genitourin Cancer. 2022;20(3):297\u2013e2976.","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"1370_CR35","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/jcm12103367","volume":"12","author":"SMH Einerhand","year":"2023","unstructured":"Einerhand SMH, Zuur LG, Wondergem MJ, et al. The implementation of FDG PET\/CT for staging bladder cancer: changes in the detection and characteristics of occult nodal metastases at upfront radical cystectomy? J Clin Med. 2023;12(10):3367.","journal-title":"J Clin Med"},{"issue":"4","key":"1370_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bju.16363","volume":"134","author":"M Longoni","year":"2024","unstructured":"Longoni M, Scilipoti P, Re C, et al. Use of 18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET\/CT for lymph node assessment before radical cystectomy in bladder cancer patients. BJU Int. 2024;134(4):636\u201343.","journal-title":"BJU Int"},{"issue":"12","key":"1370_CR37","doi-asserted-by":"publisher","first-page":"e8339","DOI":"10.1016\/j.urolonc.2021.04.027","volume":"39","author":"M Moussa","year":"2021","unstructured":"Moussa M, Chakra MA, Saad W, Dellis A, Papatsoris A. The role of 18F-FDG PET\/CT scan compared to CT scan alone for lymph node staging before radical cystectomy in patients with bladder cancer. Urol Oncol. 2021;39(12):e8339\u201383317.","journal-title":"Urol Oncol"},{"key":"1370_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07287-y","author":"TSC Ng","year":"2025","unstructured":"Ng TSC, Liu M, Robertson M, et al. A pilot study of [18F]F-fluciclovine positron emission tomography\/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07287-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1370_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41824-023-00170-9","volume":"7","author":"V Pihl","year":"2023","unstructured":"Pihl V, Markus M, Abrahamsson J, et al. FDG-PET\/CT for lymph node staging prior to radical cystectomy. Eur J Hybrid Imaging. 2023;7(1):13.","journal-title":"Eur J Hybrid Imaging"},{"key":"1370_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07239-6","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, Schmid HP, Kunte SC, et al. 68Ga-FAPI and 18F-FAPI PET\/CT for detection of nodal metastases prior to radical cystectomy in high-risk urothelial carcinoma patients. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07239-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1370_CR41","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.clgc.2023.02.004","volume":"21","author":"N van Ginkel","year":"2023","unstructured":"van Ginkel N, van Gennep EJ, Oosterbaan L, et al. Added clinical value of 18F-FDG-PET\/CT to stage patients with high-risk non-muscle invasive bladder cancer before radical cystectomy. Clin Genitourin Cancer. 2023;21(3):342\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1370_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.euf.2022.08.015","volume":"9","author":"E Gresser","year":"2023","unstructured":"Gresser E, Wo\u017anicki P, Messmer K, et al. Radiomics signature using manual versus automated segmentation for lymph node staging of bladder cancer. Eur Urol Focus. 2023;9(1):145\u201353.","journal-title":"Eur Urol Focus"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-026-01370-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:42:14Z","timestamp":1792665734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-026-01370-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1007\/s11934-026-01370-z","relation":{},"ISSN":["1534-6285"],"issn-type":[{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"58"}}